Lilly's diabetes drug peglispro outperforms Lantus in 3 trials

05/13/2014 | Reuters

Data from several Phase III trials showed that Eli Lilly and Co.'s basal insulin peglispro was more effective than Sanofi's Lantus in lowering blood glucose levels among patients with type 2 diabetes, the company said. Lilly plans to submit the drug for regulatory review in the U.S. and Europe early next year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY